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Abstract
Background: Heterozygous mutations in the gene encoding renin (REN) cause autosomal dominant tubulointerstitial
kidney disease (ADTKD), early-onset anaemia and hyperuricaemia; only four different mutations have been described in
the published literature to date. We report a novel dominant REN mutation discovered in an individual after forty years
of renal disease.
Case presentation: A 57 year old Caucasian woman with chronic kidney disease stage five was reviewed in a regional
joint renal genetics clinic. She had initially been diagnosed with chronic pyelonephritis in adolescence, around the same
time that she was investigated for anaemia out of keeping with her degree of renal impairment. Hyperuricaemia was
identified in her twenties following an episode of gout. A diagnosis of ADTKD was not made until the age of 37 years,
when her mother was also found to have kidney disease and commenced haemodialysis. The patient’s renal function
continued to slowly deteriorate and, twenty years later, her sister was worked up as a potential donor for kidney
transplantation. Revisiting the maternal family history during the transplant work up prompted a referral to clinical
genetics and urgent REN genetic testing was requested for the patient, leading to discovery of a heterozygous
mutation in the REN gene: c.49 T > C, p.(Trp17Arg). This variant was not identified in her otherwise healthy sister,
allowing pre-emptive live renal transplantation to take place shortly afterwards.
Conclusions: In an era where genetic testing is becoming much more readily available, this case highlights the
importance of considering a genetic aetiology in all patients with long-standing renal disease and a relevant family
history. Establishing a genetic diagnosis of ADTKD-REN in this individual with chronic anaemia, hyperuricaemia and
slowly progressive renal impairment helped to identify a suitable live kidney donor and allowed successful pre-emptive
transplantation to take place.
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Background
Heterozygous mutations in the genes encoding uromodu-
lin (UMOD), [1] hepatocyte nuclear factor 1β (HNF1B),
[2] renin (REN) [3] and mucin-1 (MUC1) [4] can result in
autosomal dominant tubulointerstitial kidney disease
(ADTKD). This has been known by several other terms in
the past, most frequently medullary cystic kidney disease.
ADTKD is characterised by progressive tubulointerstitial
fibrosis and development of end-stage renal disease
(ESRD). [5] Other clinical features include a positive fam-
ily history in the majority of cases, bland urinary sediment
with little or no proteinuria, normal or small-sized kidneys
on renal imaging and normotension during the early
stages of the disease. [6–8] The prevalence is unknown;
however, it is likely that many cases remain undetected
given the lack of standardised diagnostic criteria and
variable terminology prior to the recent Kidney Disease:
Improving Global Outcomes consensus report. [5] As
genetic testing for the genes known to be associated with
ADTKD becomes more widely available in routine clinical
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practice, it will be important to increase awareness of the
condition amongst nephrologists and other health care
professionals who may have affected patients without a
genetic diagnosis.
Certain factors can be helpful in differentiating the
various subtypes of ADTKD. ADTKD-UMOD is classic-
ally associated with hyperuricaemia and gout, secondary
to a decreased fractional excretion of urate. [8] ADTKD-
HNF1B may be accompanied by a variety of extra-renal
phenotypes, including diabetes mellitus, genital tract
malformations and abnormal liver function. [9] The
hallmark of ADTKD-REN is early-onset anaemia out of
proportion to the level of kidney failure. [3] Other findings
in patients with REN mutations include mild hypotension,
an increased risk of acute kidney injury (AKI), hyperuri-
caemia and hyperkalaemia [5].
REN is located on chromosome 1 and is mainly
expressed in granular cells in the juxtaglomerular appar-
atus. It encodes preprorenin, which contains a signal
sequence that targets it to the endoplasmic reticulum for
glycosylation and proteolytic processing to produce
prorenin and subsequently renin. [10] Renin is a prote-
ase that cleaves angiotensinogen to angiotensin and
stimulates aldosterone production. Mutations in the
REN gene lead to intracellular accumulation of abnormal
protein, resulting in apoptosis of renin-producing cells in
the juxtaglomerular apparatus with consequent nephron
loss and progressive chronic kidney disease (CKD). [3] To
date, only four different heterozygous REN mutations have
been reported in the published literature (Fig. 1). [3, 11, 12]
All are localised to exon 1, which encodes the signal se-
quence. In this case report, we describe a novel dominant
REN mutation discovered as part of a transplant work up
and aim to highlight the importance of investigating a
genetic diagnosis in patients with long-standing renal
disease and a relevant family history.
Case presentation
A 57 year old White British woman with CKD stage five
was referred to the regional joint renal genetics clinic
after her sister was noted to have a family history of
renal disease during work up as a potential live kidney
donor. The patient had been under nephrological follow
up since adolescence, when she was incidentally discov-
ered to have mild renal impairment (Fig. 2). An
intravenous pyelogram performed at the time showed
that both kidneys were small with decreased cortical
thickness and the most likely diagnosis was felt to be
chronic pyelonephritis. Ultrasound scanning confirmed
small kidneys with no overt renal cysts observed;
urinalysis was consistently bland. She had also been
investigated for symptoms of marked tiredness as a
teenager and was found to be anaemic with a haemoglo-
bin value of approximately 90 g/L. This was felt to be
out of keeping with her level of kidney function at the
time and remained unexplained despite extensive
investigation. She developed gout in her twenties and
her serum uric acid level was measured at 550 μmol/L;
treatment with allopurinol was initiated. She remained
under renal follow up and her kidney function continued
to slowly deteriorate. Her haemoglobin level remained
stable at around 100 g/L after initial treatment with iron
and later an erythropoiesis-stimulating agent (ESA).
When she was aged 37 years, one of the nephrology
team noted that her mother had recently commenced
haemodialysis. As both mother and daughter had
presented with slowly progressive CKD, bland urinary
sediment and small kidneys on renal imaging, the most
likely diagnosis was now felt to be ADTKD.
A detailed family history revealed that the patient’s
maternal grandmother had been told she had small kid-
neys but no further clinical details were available (Fig. 3).
The patient’s mother was identified as having mild CKD
and hypertension at the age of 65 years during a routine
health screen; renal ultrasound scanning at the time
showed two small kidneys. Her renal function continued
to decline and she commenced haemodialysis at the age
of 70 years, before passing away 5 years later due to
infective endocarditis. The patient’s siblings were all
reported as being healthy.
Fig. 1 Schematic of the REN gene; the amino acid sequence of the signal peptide is shown below with the locations of the published mutations
(indicated by the black arrows) and novel mutation described in this case report (indicated by the red arrow) identified
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By the time the patient was reviewed in the renal gen-
etics clinic, her estimated glomerular filtration rate had
fallen to 12 and she was hoping to undergo imminent
pre-emptive live renal transplantation with her sister as
the donor. Given her clinical diagnosis of ADTKD,
hyperuricaemia and history of young-onset anaemia, ur-
gent next generation sequencing was performed using
the Illumina TruSight One sequencing kit and the data
was analysed to search for pathogenic variants in HNF1B
(NM_000458.2), REN (NM_000537.3) and UMOD
(NM_003361.2). The full coding regions (+/−five base
pairs) of all three genes were sequenced to a depth of 20
fold or more, with analytical sensitivity of 98.3%–100%
(95% confidence intervals). This identified a heterozy-
gous and likely pathogenic variant in the REN gene:
c.49 T > C, p.(Trp17Arg); no abnormalities were
detected in HNF1B or UMOD (Fig. 4). Although this
sequence change has not previously been reported in the
Fig. 2 Timeline showing significant events in the course of the proband’s renal disease that led to the eventual diagnosis of ADTKD-REN.
Abbreviations: ADTKD, autosomal dominant tubulointerstitial kidney disease
Fig. 3 Pedigree of reported family. The REN phenotype is indicated below the relevant symbol where known. Black symbols denote affected
individuals with confirmed renal disease. The proband is marked with an arrow
Clissold et al. BMC Nephrology  (2017) 18:234 Page 3 of 6
published literature, missense pathogenic mutations in
the same region of REN have been described and associ-
ated with a similar phenotype. [3, 11, 12] The c.49 T > C
variant alters a highly conserved nucleotide and weakly
conserved amino acid in the aspartic peptidase do-
main of renin. Although in silico analyses are incon-
sistent and classify the variant from tolerated to
possibly damaging, it has not been reported in the
Exome Aggregation Consortium, Exome Sequencing
Project or 1000 Genomes Project and is therefore
very rare. [13–15] Functional studies have shown that
a mutation in the adjacent amino acid, p.(Leu16Arg),
prevents prorenin and renin biosynthesis and secre-
tion. [3] Therefore, it was considered highly likely
that the REN: c.49 T > C, p.(Trp17Arg) variant was
the cause of disease in this patient. Unpublished
observations presented by Vincent Morinière and
colleagues at the 43rd Annual Meeting and Scientific
Exposition of the American Society of Nephrology in
2010 include discovery of the same p.(Trp17Arg) REN
mutation in an individual with chronic tubulointersti-
tial nephritis and hyperuricaemia with a family history
of both tubulointerstitial kidney disease and gout,
providing further evidence for the pathogenicity of
this variant.
The patient’s sister commenced work up as a live kid-
ney donor aged 53 years. She was normotensive with
bland urinalysis and a serum creatinine of 72 μmol/L.
Her serum urate level was also within normal limits at
250 μmol/L. Renal ultrasound scanning suggested a
slight size discrepancy between the right and left kidneys
of approximately 1.6 cm; she went on to have magnetic
resonance angiography of the kidney, which showed no
evidence of narrowing or dilatation of the renal arteries.
Urgent REN genetic testing excluded the c.49 T > C
pathogenic variant identified in her sister (Fig. 4). This
allowed pre-emptive live donor transplantation with a
0:0:0 HLA mismatch to take place shortly afterwards.
The patient’s serum creatinine was 124 μmol/L one month
post-transplant and 139 μmol/L when last checked; her
Fig. 4 Sanger sequencing traces for the pathogenic REN variant, c.49 T > C: present in proband (upper panel) and absent in unaffected sibling
and random normal control (middle and lower panels, respectively)
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haemoglobin levels have remained approximately 100 g/L
despite stopping treatment with an ESA at the time of the
transplant.
Discussion
This case highlights the importance of revisiting an
individual’s clinical diagnosis each time a new piece of
medical information becomes available. Mild renal impair-
ment and unexplained anaemia were detected in our pa-
tient during her teenage years. Young-onset anaemia
disproportionate to the degree of renal impairment is now
known to be associated with ADTKD-REN. Haemoglobin
levels tend to normalise during puberty; the reason for this
remains unclear, although increased testosterone secretion
after adolescence in males has been hypothesised as a
possible cause. [3] She suffered her first episode of gout in
her twenties and was found to be hyperuricaemic. Ear-
ly-onset gout in a young female with mild CKD provided
an early clue to the later diagnosis of ADTKD. Raised
serum urate levels in individuals with REN mutations are
likely due to increased reabsorption of urate in the prox-
imal tubule. The production of normal renin is signifi-
cantly reduced, resulting in low renin and aldosterone
levels and subsequently mild hypotension and
hyperkalaemia. This relative hypotension stimulates the
reabsorption of sodium in the proximal tubule, which
consequently leads to an increase in urate reabsorption
and hyperuricaemia. [3, 11].
Discovery of the maternal family history of renal
disease in this case led to the clinical diagnosis of
ADTKD in our patient approximately 20 years after
her renal impairment was first identified in the 1970s.
Reviewing the family history again 20 years later as
part of her sister’s live kidney donor work up led to
the genetic diagnosis of ADTKD-REN in 2015.
Heterozygous mutations in the REN gene were first
recognised as a cause of ADTKD in 2009 and genetic
testing is available as part of routine clinical practice
in the United Kingdom despite only a handful of
cases being described so far. [3, 11, 12] Several renal
genetics clinics have been set up over the past decade
in line with major advances in DNA sequencing tech-
nology and a rapidly expanding knowledge base; the
first joint clinic covering Devon and Cornwall started
in 2012. Establishing a genetic diagnosis has multiple
advantages for individuals with renal disease and their
families. Genetic testing may identify a condition with
specific therapeutic options and can prevent the need
for renal biopsy in affected family members. It also
has an important role in the assessment of potential
kidney donors within the family, as demonstrated in
this case report. More accurate information about in-
dividual prognosis can be given when the genetic
diagnosis is known and the option of both genetic
counselling and pre-implantation genetic diagnosis
can be discussed. It can also lead to participation in
research projects and clinical trials. Finally, the
therapeutic power of knowledge after potentially many
years without a definite diagnosis cannot be
underestimated; this is particularly relevant in a con-
dition like ADTKD where many of the clinical and
histological findings are often non-specific. The pa-
tient’s perspective of this case report highlights many
of these points: “It has been hugely beneficial to me
to be able to undergo genetic testing and to have
finally been given a diagnosis after all these years of
suffering renal impairment. There have been numerous
tests carried out over the years and each time I was
told there was no conclusion that anybody could come
to that would determine the cause of my renal failure,
which I found hugely frustrating. Because of the
genetic testing now available, my sister has been able
to donate a kidney and this has completely trans-
formed my life. Without her undergoing this test, it
may not have been possible for her to go on to donate.
This has also been extremely valuable for the rest of
the family. My brother has been tested and found not
to carry the mutation so subsequently his children are
not affected either, which has brought great relief and
peace of mind to them all. Other members of the
family are currently being tested.”
There is no randomised controlled trial data avail-
able for ADTKD. [5] Fludrocortisone has been used
successfully in one ten-year-old patient with ADTKD-
REN to increase both blood pressure and estimated
glomerular filtration rate. Fludrocortisone should
decrease abnormal renin production via feedback
inhibition; this in turn should lead to less cell injury
and may be beneficial in preserving renal function in
the long term. [11] In terms of general treatment,
patients with REN mutations should be managed
according to established CKD guidelines. [16]
However, they have an increased risk of volume de-
pletion and AKI due to the renin-angiotensin system
dysfunction that is seen. A low-salt diet, which is
often recommended in CKD, should be avoided as it
may exacerbate volume depletion. [5] Diuretics can
worsen both hyperuricaemia and volume depletion so
should be used with caution. [17] Individuals with
ADTKD-REN are also likely to be particularly vulnerable
to the acute decline in renal impairment that can be seen
with nonsteroidal anti-inflammatory drugs. [11] Anaemia
can be treated with erythropoiesis-stimulating agents. [3]
As in this case, renal transplantation is the treatment of
choice for ESRD as there is no disease recurrence in the
graft. [5] Unlike for adult-onset disorders, children at risk
of inheriting a REN mutation should be referred to a
paediatric nephrology team as the disease frequently
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presents during childhood and they are likely to benefit
from early management.
Conclusions
In summary, we describe a novel dominant mutation
in the REN gene in an individual with long-standing
anaemia, hyperuricaemia and slowly progressive
CKD. This case highlights the importance of revisit-
ing the possibility of an underlying genetic cause in
patients with long-standing renal disease and a rele-
vant family history. Establishing a genetic diagnosis
of ADTKD-REN in this individual after 40 years of
renal disease helped to identify a suitable kidney
donor and allowed successful pre-emptive live renal
transplantation to take place.
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